Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy After Breast Cancer
NCT07502820Phase 3Recruiting
- Sponsor
- Karolinska Institutet
- Start
- Apr 2026
- Primary completion
- Aug 2036
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tamoxifen in breast cancer, sponsored by Karolinska Institutet. Started Apr 2026; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07502820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502820.